Deal Watch: Molecular Templates Aligns With Vertex On Optimizing Stem Cell Candidates
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.
You may also be interested in...
The new collaboration announced 17 August is worth up to $475m in near-term upfront payments plus undisclosed milestone fees and royalties up to 24%.
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
A review of biopharma start-up dealmaking and financing activity from October through December 2019, based on data from Strategic Transactions, showed a large rise in fundraising transactions from Q3 to Q4 of last year.